Brief: VolitionRx Updates Progress Of Nu.Q NETs Test Adoption
07/05/2025 13:35
May 7 (Reuters) - VolitionRX Ltd VNRX.A: VOLITIONRX LIMITED: OUTLINES BROAD STRATEGY TO BECOME THE 'NETS COMPANY' WORLDWIDE THROUGH LICENSING AND UPDATES PROGRESS OF NU.Q® NETS TEST ADOPTION Source text: ID:nPn6zxMgpa Further company coverage: VNRX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems